Login
Global healthcare provider acquires Australian pharmaceutical partner
The diversified healthcare services business Uniphar has worked with Baker McKenzie on the acquisition of the Asia-Pacific pharmaceutical supplier Orspec.
Jessica Penny
Firm: Baker McKenzie (Uniphar)
To continue reading the rest of this article, please log in.
Create free account to get unlimited news articles and more!
Deal: Baker McKenzie has advised Uniphar (LON: UPR) on acquiring specialty pharmaceutical partner Orspec Group.
Areas: Merger and acquisition, pharmaceuticals
Value: Undisclosed
Key players: The Baker McKenzie team was led by partner Ben McLaughlin, with support from Ciarán O’Brien, Jamie Sung, Amy Middlebrook, Dao Yi Lim, Alex Hewitt, Taylor Zhao, Brett Walker and Jo Grange.
Deal significance: With Uniphar active in Europe and the USA, the acquisition of Australia-headquartered Orspec Pharma will expand its operations into the Asia-Pacific market.
According to Uniphar, Orspec Pharma “specialises in the supply of unlicensed medicines and the delivery of expanded access programs across the region”.
“We are delighted to assist our client Uniphar on their expansion into Australia and Asia-Pacific,” Mr McLaughlin said.
Uniphar group chief executive Ger Rabbette said the acquisition “will support our goal of becoming a global leader in product access services”.
Uniphar is an Ireland-based organisation with a workforce of 2,900 and delivers to 160 countries worldwide. In 2021, they generated revenue of €1.9 billion.
